Table 4.

Propensity adjusted treatment effect analyses for survival outcomes among patients with triple-negative breast cancer residual disease after neoadjuvant chemotherapy

Adjuvant capecitabine (± other chemotherapy; n = 202) versus no adjuvant therapy (n = 298)
	Hazard ratio	95% CI	P value (robust)
RFS	0.70	0.54-0.91	0.008
DRFS	0.71	0.54-0.93	0.01
OS	0.66	0.49-0.90	0.009

Adjuvant capecitabine alone (n = 189) versus no adjuvant therapy (n = 298)
	Hazard ratio	95% CI	P value (robust)
RFS	0.67	0.52-0.88	0.004
DRFS	0.68	0.51-0.90	0.007
OS	0.63	0.46-0.87	0.004

Adjuvant capecitabine alone (n = 189) versus other adjuvant chemotherapy (n = 109)
	Hazard ratio	95% CI	P value (robust)
RFS	0.79	0.47-1.31	0.4
DRFS	0.75	0.44-1.29	0.3
OS	0.92	0.49-1.75	0.8

Any adjuvant therapy (n = 363) versus no adjuvant therapy (n = 298)
	Hazard ratio	95% CI	P value (robust)
RFS	0.79	0.62-1.00	0.06
DRFS	0.78	0.61-1.004	0.06
OS	0.71	0.54-0.93	0.01

Adjuvant (non-capecitabine) chemotherapy (n = 109) versus no adjuvant therapy (n = 298)
	Hazard ratio	95% CI	P value (robust)
RFS	0.90	0.57-1.42	0.7
DRFS	0.84	0.52-1.34	0.5
OS	0.63	0.37-1.08	0.08

P values that reached statistical significance (P < 0.05) are in bold.

CI, confidence interval; DRFS, distant recurrence-free survival; OS, overall survival; RFS, recurrence-free survival.